We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Biomedical Tattoo Detects Cancer-Associated Hypercalcemia

By HospiMedica International staff writers
Posted on 01 May 2018
Print article
Image: A new study explains how increased calcium levels trigger the production of melanin, causing a mole to form (Photo courtesy of ETH Zurich).
Image: A new study explains how increased calcium levels trigger the production of melanin, causing a mole to form (Photo courtesy of ETH Zurich).
A new study describes how a mole-like synthetic implant recognizes the elevated levels of calcium in the blood associated with incipient prostate, lung, colon, and breast cancer tumors.

Developed by researchers at ETH Zurich (Switzerland) and the University of Basel (Switzerland), the so-called early warning system is comprised of an encapsulated gene network integrated into human body cells implanted under the skin, where it constantly monitors blood calcium levels. When calcium levels exceed a pre-determined threshold, a synthetic signaling cascade expresses transgenic tyrosinase, which triggers the production of melanin in the genetically modified cells. The skin then forms a brown mole that is visible to the naked eye.

The researchers validated the design in wild-type mice inoculated with hypercalcemic breast and colon adenocarcinoma cells. The mice, which were implanted with the subcutaneous encapsulated engineered cells, all developed tattoos, whereas no tattoos were seen in animals inoculated with normo-calcemic tumor cells. The study also confirmed that the synthetic biomedical mole could not only be detected with the naked eye, but could also optically quantified. All animals remained asymptomatic throughout the 38-day experimental period. The study was published on April 18, 2018, in Science Translational Medicine.

“It recognizes the four most common types of cancer--prostate, lung, colon, and breast cancer--at a very early stage, namely when the level of calcium in the blood is elevated due to the developing tumor,” said senior author Professor Martin Fussenegger, PhD, of the ETH department of biosystems science and engineering. “An implant carrier should then see a doctor for further evaluation after the mole appears. It is no reason to panic; the mole does not mean that the person is likely to die soon.”

“It is intended primarily for self-monitoring, making it very cost effective. However, for those who would prefer not to deal with the constant stress, an implant can also be used that develops a mark visible only under a red light,” concluded Professor Fussenegger. “The disadvantage is that the service life of such an implant is limited. Encapsulated living cells last for about a year, according to other studies. After that, they must be inactivated and replaced.”

Calcium is an essential element vital to the health of the muscular, circulatory, and digestive systems; is indispensable to the building of bone; and supports synthesis and function of blood cells. For example, it regulates the contraction of muscles, nerve conduction, and the clotting of blood. As a result, intra- and extracellular calcium levels are tightly regulated by the body. Cancer can cause hypercalcemia by bone degradation, releasing excess calcium into the blood; some tumors can produce proteins that mimic parathyroid hormone; and others can affect the ability of the kidneys to remove excess calcium.

Related Links:
ETH Zurich
University of Basel

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Hospital Data Analytics Software
OR Companion
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.